PRVB News and Press, Provention Bio Inc. From 05/06/21

Provention Bio (PRVB): Q1 GAAP EPS of -$0.52 misses by $0.05.As of March 31, 2021, Provention Bio had cash and cash equivalents and marketable securities of $207.2 million.Press Release For further details see: Provention Bio EPS misses by $0.05

Provention Bio Reports First Quarter 2021 Financial Results and Provides Business Update PR Newswire RED BANK, N.J. , May 6, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune...

Provention Bio Announces the Grant of Inducement Awards PR Newswire RED BANK, N.J. , May 3, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB) (the "Company"), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, to...

Provention Bio to Report First Quarter 2021 Financial Results on May 6, 2021 PR Newswire RED BANK, N.J. , April 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated...

Gainers: [[CYBE]] +5.7%. [[JG]] +4.8%. [[MVIS]] +4.7%. [[GOOG]] +4.5%. [[RNWK]] +4.3%.Losers: [[PRVB]] -7.4%. [[ENPH]] -7.1%. [[GRTS]] -5.7%. [[FFIV]] -5.6%. [[CMPS]] -5.4%. For further details see: CYBE, GOOG, PRVB and ENPH among after-hours movers

Provention Bio (PRVB) highlights potential delays in BLA approval timelines for its diabetes treatment teplizumab following pharmacokinetic ((PK)) comparability considerations raised by the U.S. FDA.The FDA reported that the PK profiles of the two drug products evaluated in the...

Provention Bio Provides Additional Regulatory Update on Biologics License Application for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals PR Newswire RED BANK, N.J. , April 27, 2021 /PRNewswire/ -- Provention...

Provention Bio is oversold, and the stock is trading at an attractive price level. I expect a sharp rebound shortly. The key question is "when" will Teplizumab be approved, not whether Teplizumab will be approved or not. Teplizumab approval will likely be delayed, and I expect the...

Gainers: Celcuity (CELC) +43%.NCS Multistage (NCSM) +39%.MEDIROM Healthcare Technologies (MRM) +31%.Natuzzi (NTZ) +24%.Affimed (AFMD) +23%.Tenax Therapeutics (TENX) +23%.Brooklyn ImmunoTherapeutics (BTX) +20%.GT Biopharma (GTBP) +16%.Sohu.com (SOHU) +15%.fuboTV (...

Provention Bio (PRVB) shares are down more than 19% in afternoon trading after the FDA "identified deficiencies" in the company's BLA for teplizumab for type 1 diabetes.RBC Capital Markets downgraded shares and SVB Leerink lowered its price target.RBC analyst Gregory Renza downgraded shares t...